Structured evidence table for Melatonin Stress Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Melatonin Stress Randomized Trial | 7 7 8 Despite a robust mechanistic basis, the existing clinical evidence regarding melatonin’s cardiovascular efficacy is fragmented and inconsistent. | 1 | Ang Song Peng (2026) | Melatonin Supplementation and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials |
| Melatonin Stress Randomized Trial | We stratified data by distinct clinical settings, including perioperative cardiac surgery, acute myocardial infarction (AMI), and heart failure with reduced ejection fraction (HFrEF). | 1 | Ang Song Peng (2026) | Melatonin Supplementation and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials |
| Melatonin Stress Randomized Trial | Background pharmacotherapy was largely uniform within CABG and HF cohorts, with the majority of patients receiving guideline-directed medical therapy including beta-blockers, statins, renin-angiotensin system inhibitors, and antiplatelet agents. | 1 | Ang Song Peng (2026) | Melatonin Supplementation and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials |
| Melatonin Stress Randomized Trial | 1 2 3 4 5 6 6 Cardiovascular disease remains the predominant driver of global mortality and morbidity worldwide, with acute coronary syndromes, heart failure, and post-surgical cardiac dysfunction representing major sources of preventable death and disability. | 1 | Ang Song Peng (2026) | Melatonin Supplementation and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials |
| Melatonin Stress Randomized Trial | Although reperfusion therapies have improved outcomes, their narrow therapeutic window and limited availability leave many patients without effective treatment, highlighting the need for effective neuroprotective strategies capable of targeting multiple interconnected pathways. | 4 | Ortiz-Martínez G (2026) | Melatonin as a Pleiotropic Modulator of Mitochondrial Function and Cellular Signaling in Ischemic Brain Injury. |
| Melatonin Stress Randomized Trial | However, clinical evidence remains limited to a small number of clinical trials, which suggest safety and possible early neurological benefit but are underpowered to determine long-term efficacy. | 4 | Ortiz-Martínez G (2026) | Melatonin as a Pleiotropic Modulator of Mitochondrial Function and Cellular Signaling in Ischemic Brain Injury. |
| Melatonin Stress Randomized Trial | Acute ischemic stroke is one of the leading causes of mortality and disability globally, characterized by a complex and temporally structured cascade of cellular and molecular events. | 4 | Ortiz-Martínez G (2026) | Melatonin as a Pleiotropic Modulator of Mitochondrial Function and Cellular Signaling in Ischemic Brain Injury. |
Source documents